On Oct 26, major Wall Street analysts update their ratings for $DexCom (DXCM.US)$, with price targets ranging from $85 to $115.
J.P. Morgan analyst Robbie Marcus downgrades to a hold rating, and adjusts the target price from $145 to $85.
BofA Securities analyst Travis Steed maintains with a buy rating.
Citi analyst Joanne Wuensch maintains with a buy rating.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $80 to $90.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $160 to $100.
Furthermore, according to the comprehensive report, the opinions of $DexCom (DXCM.US)$'s main analysts recently are as follows:
DexCom has effectively bolstered investor confidence in its revenue target for 2025, which includes a minimal contribution from Stelo. It is anticipated that earnings estimates may rise in response to the company's return to double-digit revenue growth.
DexCom's third-quarter revenue outperformance was propelled by a record number of new patient initiations, yet earnings were affected by diminished gross margins. Momentum for DexCom is gathering as the year concludes, with a clear trajectory towards achieving at least a 15% year-over-year growth by 2025.
DexCom's third-quarter sales surpassed expectations, driven by a stronger than anticipated performance internationally, although the U.S. figures fell short relative to estimates. This discrepancy in the U.S. market is attributed to a decrease in new patient additions in the second quarter and anticipated effects from product mix. The company's guidance for sales and margins remains steady for 2024, in line with their targets for 2025.
Here are the latest investment ratings and price targets for $DexCom (DXCM.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月26日，多家華爾街大行更新了$德康醫療 (DXCM.US)$的評級，目標價介於85美元至115美元。
摩根大通分析師Robbie Marcus下調至持有評級，並將目標價從145美元下調至85美元。
美銀證券分析師Travis Steed維持買入評級。
花旗分析師Joanne Wuensch維持買入評級。
富國集團分析師Larry Biegelsen維持買入評級，並將目標價從80美元上調至90美元。
富瑞集團分析師Matthew Taylor維持買入評級，並將目標價從160美元下調至100美元。
此外，綜合報道，$德康醫療 (DXCM.US)$近期主要分析師觀點如下：
德康醫療已經有效地增強了投資者對其2025年營業收入目標的信懇智能，其中包括Stelo的最低貢獻。預計隨着公司重返兩位數營業收入增長，盈利預估可能會有所上升。
德康醫療第三季度營業收入的超預期表現受到了新患者啓動數量創紀錄的推動，但盈利受到了毛利率下降的影響。隨着年底臨近，德康醫療的勢頭正在積聚，朝着至少在2025年實現15%的年同比增長的明確軌跡發展。
德康醫療第三季度銷售表現超出預期，主要受國際表現強於預期的推動，儘管美國數據相對估計值偏低。美國市場的這種差異歸因於第二季度新患者增加數量的減少以及產品組合的預期影響。公司對2024年銷售額和毛利率的指導保持穩健，符合他們對2025年目標的預期。
以下爲今日7位分析師對$德康醫療 (DXCM.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
